| |
Latest 10 SEC filings (by transaction date) for NGM within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 18/24 | Jan 16/24 | Lieu Hsiao D | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,430 | $1.34 |
Jan 18/24 | Jan 16/24 | Perlich Irene | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -1,025 | $1.34 |
Jan 18/24 | Jan 16/24 | Pierce Valerie L | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,021 | $1.34 |
Jan 18/24 | Jan 16/24 | Woodhouse David J | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -13,032 | $1.34 |
Dec 4/23 | Dec 1/23 | Viret Jean-Frederic | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 450,000 | |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 16/23 | Goeddel David V | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 16/23 | Goeddel David V | Direct Ownership | Common Stock | P - Open market or private purchase | 1,460 | $0.621 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for NGM within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 18/24 | Jan 16/24 | Lieu Hsiao D | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,430 | $1.34 |
Jan 18/24 | Jan 16/24 | Perlich Irene | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -1,025 | $1.34 |
Jan 18/24 | Jan 16/24 | Pierce Valerie L | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,021 | $1.34 |
Jan 18/24 | Jan 16/24 | Woodhouse David J | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -13,032 | $1.34 |
Dec 4/23 | Dec 1/23 | Viret Jean-Frederic | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 450,000 | |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 15/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 16,791 | $0.708 |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Nov 17/23 | Nov 15/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 16,791 | $0.708 |
Nov 17/23 | Nov 16/23 | Column Group L P | Indirect Ownership | Common Stock | P - Open market or private purchase | 5,840 | $0.621 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Cerevel Therapeutics Hold (OQ:CERE) |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |